3193 results for «278»
3193 results
Introducing the next era of coronary intravascular lithotripsy: an aero-volution in calcium modification
27 Feb 2026 – From Euro4C Annual Meeting
Explore the next era of coronary intravascular lithotripsy featuring innovative technology for calcium modification. This session covers the unique mechanism of action, practical application in complex cases, and recent clinical evidence supporting its safety and efficacy.
Hot topics and evidence on structural interventions in 2025 and 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...
Novel Hertz Contact intravascular lithotripsy: calcium fragmentation with zero trade-offs
27 Feb 2026 – From Euro4C Annual Meeting
This session introduces the novel Hertz Contact intravascular lithotripsy system, designed for effective calcium fragmentation without trade-offs. It covers lesion types amenable to treatment, system mechanism, optimization tips, and discusses real-world cases along with supporting clinical trial evidence.
Prevention and management of TAVI complications
14 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...
Primary mitral TEER in small anatomy - LIVE case
15 Feb 2026 – From PCR Tokyo Valves 2026
An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).
One Pascal ACE device was implanted.
LIVE Educational Case from Nagoya...
Guidelines update
15 Feb 2026 – From PCR Tokyo Valves 2026
This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...
Future devices and techniques for structural heart disease
15 Feb 2026 – From PCR Tokyo Valves 2026
This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.
A randomised, multicenter, non-inferiority comparison of intravascular lithotripsy and super-high-pressure non-compliant balloons for treatment of calcified and refractory coronary lesions - The VICTORY trial
27 Oct 2025
Mirvat Alasnag provides her take on the VICTORY trial presented by Matthias Bossard at TCT 2025 in San Francisco.
Author
Impella percutaneous ventricular assist device malrotation in social media: a call to action
20 Apr 2023
The data from this study suggest that, from a SoMe perspective, correct Impella orientation is often overlooked, and that Impella malrotation is a common issue in real-world clinical practice, potentially associated with relevant complications.
Author
Author
Author
Author
Author
30 years of primary PCI – a tale of perseverance
16 May 2023
Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
Ivus or angiography guidance for PCI in complex coronary bifurcation lesions (DKCRUSH-VIII)
31 Mar 2026
Nicola Ryan provides her take on DKCRUSH-VIII, a randomised controlled trial comparing IVUS versus angiography guidance for PCI, predominantly using the DKCRUSH technique in patients with complex bifurcation lesions, as presented by Shaoliang Chen at ACC.26 in New Orleans.
Author
Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes: The multicenter, randomized, blinded, IVUS-ACS Trial
09 Apr 2024
Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)
Author
Author
